Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1990 Aug;212(2):150–154. doi: 10.1097/00000658-199008000-00006

Clinicopathologic comparisons between estrogen receptor-positive and -negative hepatocellular carcinomas.

N Nagasue 1, H Kohno 1, Y C Chang 1, A Yamanoi 1, T Nakamura 1, H Yukaya 1, T Hayashi 1
PMCID: PMC1358049  PMID: 2165386

Abstract

During the past 8 years, estrogen receptors (ERs) in the cytosol of hepatocellular carcinoma (HCC) were assayed in 66 unselected patients without preceding treatments on whom radical hepatic resection was performed. Twenty-six patients had ERs of 0.9 to 13.4 fmol/mg protein with a mean dissociation constant of 7.8 x 10(-10) M. The remaining 40 patients had no detectable amount of the receptor. There were no substantial differences between the ER-positive and ER-negative groups in preoperative clinical and laboratory data such as sex, age, alcohol abuse, underlying liver disease, and hepatic functions. Large tumors were more common in the ER-negative group and therefore the incidence of major hepatic resection was significantly higher in this group. Histopathologic studies revealed no substantial differences between the two groups. Operative mortality rate was 11.5% in the ER-positive and 12.5% in the ER-negative group. Excluding eight operative deaths, the rate of tumor recurrence in the residual liver and long-term survival rate were identical for the two study groups. The current results may indicate that the presence or absence of ERs in human HCC does not correlate to either biologic or pathologic characteristics of this tumor, but the true role of ERs in human HCC remains to be elucidated.

Full text

PDF
150

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baum J. K., Bookstein J. J., Holtz F., Klein E. W. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973 Oct 27;2(7835):926–929. doi: 10.1016/s0140-6736(73)92594-4. [DOI] [PubMed] [Google Scholar]
  2. Bühler H., Pirovino M., Akobiantz A., Altorfer J., Weitzel M., Maranta E., Schmid M. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology. 1982 Apr;82(4):775–782. [PubMed] [Google Scholar]
  3. Chopra I. J., Tulchinsky D., Greenway F. L. Estrogen-androgen imbalance in hepatic cirrhosis. Studies in 13 male patients. Ann Intern Med. 1973 Aug;79(2):198–203. doi: 10.7326/0003-4819-79-2-198. [DOI] [PubMed] [Google Scholar]
  4. Duffy M. J., Duffy G. J. Estradiol receptors in human liver. J Steroid Biochem. 1978 Mar;9(3):233–235. doi: 10.1016/0022-4731(78)90154-1. [DOI] [PubMed] [Google Scholar]
  5. EDMONDSON H. A., STEINER P. E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954 May;7(3):462–503. doi: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  6. Edmondson H. A., Reynolds T. B., Henderson B., Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med. 1977 Feb;86(2):180–182. doi: 10.7326/0003-4819-86-2-180. [DOI] [PubMed] [Google Scholar]
  7. Friedman M. A., Demanes D. J., Hoffman P. G., Jr Hepatomas: hormone receptors and therapy. Am J Med. 1982 Sep;73(3):362–366. [PubMed] [Google Scholar]
  8. Green J. R., Mowat N. A., Fisher R. A., Anderson D. C. Plasma oestrogens in men with chronic liver disease. Gut. 1976 Jun;17(6):426–430. doi: 10.1136/gut.17.6.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Higashi S., Tomita T., Mizumoto R., Nakakuki K. Development of hepatoma in rats following oral administration of synthetic estrogen and progestogen. Gan. 1980 Aug;71(4):576–577. [PubMed] [Google Scholar]
  10. Lang R., Redmann U. Non-mutagenicity of some sex hormones in the Ames salmonella/microsome mutagenicity test. Mutat Res. 1979 Aug;67(4):361–365. doi: 10.1016/0165-1218(79)90033-8. [DOI] [PubMed] [Google Scholar]
  11. Li S. A., Li J. J. Changes in estrogen receptor levels during DES-induced hepatocarcinogenesis in the Syrian hamster fed alpha-naphthoflavone. J Steroid Biochem. 1981 Dec;15:387–392. doi: 10.1016/0022-4731(81)90302-2. [DOI] [PubMed] [Google Scholar]
  12. Nagasue N., Chang Y. C., Hayashi T., Galizia G., Kohno H., Nakamura T., Yukaya H. Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. Ann Surg. 1989 Apr;209(4):424–427. doi: 10.1097/00000658-198904000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nagasue N., Ito A., Yukaya H., Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology. 1985 Sep;89(3):643–647. doi: 10.1016/0016-5085(85)90463-9. [DOI] [PubMed] [Google Scholar]
  14. Nagasue N., Ito A., Yukaya H., Ogawa Y. Estrogen receptors in hepatocellular carcinoma. Cancer. 1986 Jan 1;57(1):87–91. doi: 10.1002/1097-0142(19860101)57:1<87::aid-cncr2820570118>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  15. Nagasue N., Kohno H., Chang Y. C., Hayashi T., Utsumi Y., Nakamura T., Yukaya H. Androgen and estrogen receptors in hepatocellular carcinoma and the surrounding liver in women. Cancer. 1989 Jan 1;63(1):112–116. doi: 10.1002/1097-0142(19890101)63:1<112::aid-cncr2820630118>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  16. Nagasue N., Ogawa Y., Yukaya H., Ohta N., Ito A. Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology. 1985 Mar;88(3):768–772. doi: 10.1016/0016-5085(85)90149-0. [DOI] [PubMed] [Google Scholar]
  17. Ohnishi S., Murakami T., Moriyama T., Mitamura K., Imawari M. Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology. 1986 May-Jun;6(3):440–443. doi: 10.1002/hep.1840060320. [DOI] [PubMed] [Google Scholar]
  18. Reznik-Schüller H. Carcinogenic effects of diethylstilbestrol in male Syrian golden hamsters and European hamsters. J Natl Cancer Inst. 1979 Apr;62(4):1083–1088. [PubMed] [Google Scholar]
  19. Steinbrecher U. P., Lisbona R., Huang S. N., Mishkin S. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci. 1981 Nov;26(11):1045–1050. doi: 10.1007/BF01314771. [DOI] [PubMed] [Google Scholar]
  20. Sumi C., Yokoro K., Kajitani T., Ito A. Synergism of diethylstilbestrol and other carcinogens in concurrent development of hepatic, mammary, and pituitary tumors in castrated male rats. J Natl Cancer Inst. 1980 Jul;65(1):169–175. [PubMed] [Google Scholar]
  21. Sumi C., Yokoro K., Matsushima R. Induction of hepatic tumors by diethylstilbestrol alone or in synergism with n-nitrosobutylurea in castrated male WF rats. J Natl Cancer Inst. 1983 May;70(5):937–942. [PubMed] [Google Scholar]
  22. Taper H. S. The effect of estradiol-17-phenylpropionate and estradiol benzoate on N-nitrosomorpholine-induced liver carcinogenesis in ovariectomized female rats. Cancer. 1978 Aug;42(2):462–467. doi: 10.1002/1097-0142(197808)42:2<462::aid-cncr2820420213>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  23. Wanless I. R., Medline A. Role of estrogens as promoters of hepatic neoplasia. Lab Invest. 1982 Mar;46(3):313–320. [PubMed] [Google Scholar]
  24. Yager J. D., Jr, Yager R. Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res. 1980 Oct;40(10):3680–3685. [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES